8-K/A: Aethlon Medical Stockholder Meeting Vote Correction

Aethlon Medical, Inc. files an amendment to correct the voting results of Proposal No. 7 from its 2026 Annual Meeting, confirming it was not approved.

Summary

• This filing is an amendment to a previous report (Form 8-K) filed on October 1, 2026.
• The amendment corrects the disclosure regarding Proposal No. 7 from the 2026 Annual Meeting of Stockholders.
• Proposal No. 7, which sought to amend the Articles of Incorporation to authorize 20,000,000 shares of preferred stock, was not approved by stockholders.
• The voting results for Proposal No. 7 were: 204,122 votes for, 9,529 votes against, 1,555 abstentions, and 184,547 broker non-votes.
• Approval required a majority of outstanding shares entitled to vote, meaning at least 355,569 affirmative votes were needed.
• As the proposal received only 204,122 votes in favor, it failed to pass, and the company's Articles of Incorporation will not be amended to authorize preferred stock.
• All other disclosures from the original Form 8-K remain unchanged.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the failure to pass a key proposal, indicating potential shareholder disagreement or lack of confidence in management's strategic proposals.

Negatives

• Stockholders did not approve the proposed amendment to authorize 20,000,000 shares of preferred stock.
• The company failed to secure the necessary majority vote (at least 355,569 shares) for Proposal No. 7.
• The failure to approve the preferred stock authorization may hinder future financing or strategic flexibility.

Risks

• The failure to authorize preferred stock could limit the company's ability to raise capital through preferred equity offerings in the future.
• The voting results may indicate a lack of complete shareholder confidence in management's proposed corporate structure changes.

Future Outlook

The filing does not contain specific forward-looking statements or guidance, other than the implication that the company's Articles of Incorporation will not be amended as proposed.

Management Comments

• The company's stockholders did not approve a proposed amendment to the Company's Articles of Incorporation to authorize 20,000,000 shares of preferred stock.
• Proposal No. 7 did not receive the affirmative vote required for approval and therefore was not approved.

Industry Context

StockSavvy.ai notes that the inability to authorize preferred stock can sometimes be a signal of shareholder concerns about potential dilution or the strategic use of such authorized shares, which is a common point of contention in corporate governance discussions within the biotech and medical technology sectors.

Corporate Governance

Stakeholder Impact

• Shareholders: The failure to approve preferred stock authorization may be viewed positively by some shareholders concerned about potential dilution, or negatively by others who believe it limits management's strategic options.

Next Steps

• The company's Articles of Incorporation will not be amended to authorize preferred stock.
• The company will continue to operate under its current charter provisions regarding authorized capital stock.

Key Dates

Keywords

Preferred Stock Authorization, Annual Meeting, Stockholder Vote, Articles of Incorporation, Corporate Governance, Shareholder Approval